Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected to show a rise in quarterly revenue when it reports results on October 29 (estimated) for the period ending September 30 2025
The Cambridge Cambridgeshire-based company is expected to report a 174.0% increase in revenue to $7.333 million from $2.68 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bicycle Therapeutics PLC is for a loss of $1.08 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $25.50, about 69.1% above its last closing price of $7.88
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.97 | -0.95 | -1.14 | Missed | -19.8 |
Mar. 31 2025 | -0.82 | -0.84 | -0.88 | Missed | -4.5 |
Dec. 31 2024 | -0.82 | -0.86 | -0.82 | Beat | 4.5 |
Sep. 30 2024 | -0.75 | -0.78 | -0.74 | Beat | 5.3 |
Jun. 30 2024 | -1.06 | -1.10 | -0.77 | Beat | 29.9 |
Mar. 31 2024 | -1.25 | -1.24 | -0.62 | Beat | 50.1 |
Dec. 31 2023 | -1.17 | -1.23 | -1.16 | Beat | 6 |
Sep. 30 2023 | -1.16 | -1.17 | -1.26 | Missed | -7.6 |
This summary was machine generated October 27 at 12:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)